FDA Approves XARELTO — Janssen Pharmaceuticals, Inc.

# FDA Approves New Oral Formulation of Janssen's XARELTO (Rivaroxaban) The U.S. Food and Drug Administration has approved Janssen Pharmaceuticals' XARELTO (rivaroxaban) oral formulation under NDA 215859, potentially strengthening the company's position in the competitive anticoagulant market as the blockbuster drug approaches generic competition. The approval could expand XARELTO's market reach and patient accessibility ahead of anticipated generic entry of rivaroxaban.